Sumitomo Mitsui DS Asset Management Company Ltd Raises Holdings in AbbVie Inc. $ABBV

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 286,491 shares of the company’s stock after acquiring an additional 5,571 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in AbbVie were worth $66,334,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. boosted its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

NYSE:ABBV opened at $220.06 on Friday. The stock has a market cap of $388.93 billion, a PE ratio of 166.71, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $226.59 and its two-hundred day moving average is $215.12.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ABBV shares. UBS Group initiated coverage on shares of AbbVie in a research note on Wednesday. They set a “neutral” rating and a $240.00 target price on the stock. Morgan Stanley raised their target price on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Wells Fargo & Company raised their price objective on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Finally, Bank of America lifted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.